• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

14.21 -0.02 (-0.11%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
News headline image
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
October 01, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗
September 29, 2026
Via Chartmill
Most active stocks in Tuesday's session ↗
September 29, 2026
Via Chartmill
These stocks are moving in today's session ↗
September 29, 2026
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
September 29, 2026
Via Chartmill
Iovance Biotherapeutics (NASDAQ:IOVA) Beats Q2 Estimates on Record Revenue, Shares Jump ↗
August 06, 2026
Via Chartmill
IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen ↗
June 29, 2026
Via Chartmill
News headline image
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
September 29, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Iovance Biotherapeutics Stock Was on Fire Today ↗
September 24, 2026
An influential investment bank resumed its coverage of the company. 
Via The Motley Fool
News headline image
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains ↗
September 19, 2026
Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter... 
Via MarketBeat
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 18, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
September 04, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 21, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance (IOVA) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy. 
Via The Motley Fool
Topics Earnings
News headline image
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? ↗
August 10, 2026
The healthcare stock is now up more than 130% this year. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Q2 Earnings Call Highlights ↗
August 06, 2026
Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded... 
Via MarketBeat
Topics Earnings
Top stock movements in today's session. ↗
August 06, 2026
Via Chartmill
News headline image
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results ↗
August 06, 2026
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should... 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
August 06, 2026
Via Chartmill
News headline image
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
August 06, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
July 30, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 17, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This Stock Is Up 74% This Year: Is It Too Late to Buy? ↗
July 08, 2026
The biotech is clearly innovative, but sometimes that's not enough. 
Via The Motley Fool
News headline image
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
July 04, 2026
Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
June 23, 2026
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 19, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 08, 2026
From Biotech Insider
Via GlobeNewswire
News headline image
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
June 03, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For? ↗
June 02, 2026
Tread carefully, but certain factors make this speculative biotech play stand out. 
Via The Motley Fool
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
June 01, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap